US5354844A
(en)
*
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
US5981273A
(en)
*
|
1991-09-30 |
1999-11-09 |
Boehringer Ingelheim Int'l. Gmbh |
Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
|
NZ244306A
(en)
*
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
JPH07505283A
(ja)
*
|
1992-03-20 |
1995-06-15 |
ベイラー・カレッジ・オブ・メディシン |
Dnaトランスポーター系および使用方法
|
EP1236473A3
(de)
*
|
1992-04-03 |
2003-01-15 |
The Regents Of The University Of California |
Selbst zusammenbaubares system zur verabreichung von polynukleotiden
|
WO1994006923A1
(en)
*
|
1992-09-24 |
1994-03-31 |
The University Of Connecticut |
Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells
|
JPH08507921A
(ja)
*
|
1993-03-19 |
1996-08-27 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
癌ワクチンの調製方法
|
DE4311651A1
(de)
*
|
1993-04-08 |
1994-10-13 |
Boehringer Ingelheim Int |
Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
|
WO1995002698A1
(en)
*
|
1993-07-12 |
1995-01-26 |
Life Technologies, Inc. |
Composition and methods for transfecting eukaryotic cells
|
DE4335025A1
(de)
*
|
1993-10-14 |
1995-04-20 |
Boehringer Ingelheim Int |
Endosomolytisch wirksame Partikel
|
EP0648493A1
(de)
*
|
1993-10-19 |
1995-04-19 |
Tadatsugu Prof. Dr. Taniguchi |
Verfahren zur Umkehrung des Phänotyps transformierter Zellen durch Transkriptionsfaktor IRF-1
|
US5928944A
(en)
*
|
1994-02-04 |
1999-07-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of adenoviral-medicated cell transfection
|
MX9603866A
(es)
*
|
1994-03-18 |
1997-03-29 |
Boehringer Ingelheim Int |
Procedimiento para el tratamiento de celulas eucarioticas.
|
WO1995026411A2
(en)
*
|
1994-03-25 |
1995-10-05 |
The Uab Research Foundation |
Composition and methods for creating syngeneic recombinant virus-producing cells
|
US5670347A
(en)
|
1994-05-11 |
1997-09-23 |
Amba Biosciences Llc |
Peptide-mediated gene transfer
|
EP0767840A2
(de)
|
1994-05-30 |
1997-04-16 |
BOEHRINGER INGELHEIM INTERNATIONAL GmbH |
Verfahren zum einbringen von fremdmaterial in höhere eukaryotische zellen
|
DE4418965A1
(de)
*
|
1994-05-31 |
1995-12-07 |
Boehringer Ingelheim Int |
Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
|
DE4426429A1
(de)
*
|
1994-07-26 |
1996-02-01 |
Boehringer Ingelheim Int |
Verfahren zum Einführen von DNA in höhere eukaryotische Zellen
|
US6468981B1
(en)
|
1994-07-29 |
2002-10-22 |
Emory University |
Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors
|
US5525606A
(en)
|
1994-08-01 |
1996-06-11 |
The United States Of America As Represented By The Department Of Health And Human Services |
Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
|
US5962311A
(en)
*
|
1994-09-08 |
1999-10-05 |
Genvec, Inc. |
Short-shafted adenoviral fiber and its use
|
US5559099A
(en)
*
|
1994-09-08 |
1996-09-24 |
Genvec, Inc. |
Penton base protein and methods of using same
|
US6465253B1
(en)
*
|
1994-09-08 |
2002-10-15 |
Genvec, Inc. |
Vectors and methods for gene transfer to cells
|
US5846782A
(en)
|
1995-11-28 |
1998-12-08 |
Genvec, Inc. |
Targeting adenovirus with use of constrained peptide motifs
|
US5965541A
(en)
*
|
1995-11-28 |
1999-10-12 |
Genvec, Inc. |
Vectors and methods for gene transfer to cells
|
US5837533A
(en)
*
|
1994-09-28 |
1998-11-17 |
American Home Products Corporation |
Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
|
US6010871A
(en)
*
|
1994-09-29 |
2000-01-04 |
Ajinomoto Co., Inc. |
Modification of peptide and protein
|
US6221959B1
(en)
|
1994-11-18 |
2001-04-24 |
Supratek Pharma, Inc. |
Polynucleotide compositions
|
US6359054B1
(en)
|
1994-11-18 |
2002-03-19 |
Supratek Pharma Inc. |
Polynucleotide compositions for intramuscular administration
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US6127525A
(en)
*
|
1995-02-21 |
2000-10-03 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral coat protein and methods of using same
|
US5770442A
(en)
*
|
1995-02-21 |
1998-06-23 |
Cornell Research Foundation, Inc. |
Chimeric adenoviral fiber protein and methods of using same
|
JP3908274B2
(ja)
*
|
1995-03-09 |
2007-04-25 |
ゲーエスエフ−フォルシュンクスツェントラム・フュア・ウムベルト・ウント・ゲズントハイト・ゲーエムベーハー |
遺伝子治療用の抗菌ペプチドをコードする治療用遺伝子を有するベクター
|
WO1996029423A1
(en)
*
|
1995-03-20 |
1996-09-26 |
Baylor College Of Medicine |
Compositions and methods for inducing infection by retroviral vectors outside of their host range
|
DE19510344C1
(de)
*
|
1995-03-22 |
1996-11-07 |
Boehringer Ingelheim Int |
Verwendung einer Tumorvakzine
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US6051429A
(en)
|
1995-06-07 |
2000-04-18 |
Life Technologies, Inc. |
Peptide-enhanced cationic lipid transfections
|
EP0874910A4
(de)
*
|
1995-06-07 |
1999-04-21 |
Life Technologies Inc |
Durch peptide erhöhte kationische lipid transfektionen
|
AU705035B2
(en)
*
|
1995-06-07 |
1999-05-13 |
Baylor College Of Medicine |
Nucleic acid transporters for delivery of nucleic acids into a cell
|
US20030069173A1
(en)
*
|
1998-03-16 |
2003-04-10 |
Life Technologies, Inc. |
Peptide-enhanced transfections
|
US6783980B2
(en)
*
|
1995-06-15 |
2004-08-31 |
Crucell Holland B.V. |
Packaging systems for human recombinant adenovirus to be used in gene therapy
|
DE69633565T3
(de)
|
1995-06-15 |
2013-01-17 |
Crucell Holland B.V. |
Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
|
US5908777A
(en)
*
|
1995-06-23 |
1999-06-01 |
University Of Pittsburgh |
Lipidic vector for nucleic acid delivery
|
GB9515356D0
(en)
*
|
1995-07-26 |
1995-09-20 |
Medical Res Council |
Improvements in or relating to delivery of nucleic acid
|
US5770720A
(en)
*
|
1995-08-30 |
1998-06-23 |
Barnes-Jewish Hospital |
Ubiquitin conjugating enzymes having transcriptional repressor activity
|
IL115199A
(en)
|
1995-09-07 |
2005-05-17 |
Opperbas Holding Bv |
Composition comprising a polynucleic acid molecule in a liposome and method using said composition
|
US6630351B1
(en)
*
|
1999-06-07 |
2003-10-07 |
Mirus Corporation |
Compositions and methods for drug delivery using pH sensitive molecules
|
CA2190304A1
(en)
*
|
1995-12-15 |
1997-06-16 |
Elazar Rabbani |
Property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses
|
AU2112697A
(en)
*
|
1996-02-09 |
1997-08-28 |
Pi-Wan Cheng |
Receptor ligand-facilitated delivery of biologically active molecules
|
DE19605548A1
(de)
*
|
1996-02-15 |
1997-09-04 |
Boehringer Ingelheim Int |
Zusammensetzung für die Transfektion höherer eukaryotischer Zellen
|
EP0904373A1
(de)
|
1996-03-14 |
1999-03-31 |
The Immune Response Corporation |
Zielgerichtete abgage von interferon-kodierenden genen
|
DE19615803A1
(de)
|
1996-04-20 |
1997-10-23 |
Boehringer Ingelheim Int |
CELO-Virus
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
CA2264012C
(en)
|
1996-08-13 |
2011-04-26 |
Chiron Corporation |
Compositions and methods for polynucleotide delivery
|
DE19632532A1
(de)
*
|
1996-08-13 |
1998-02-19 |
Boehringer Ingelheim Int |
Verfahren zur Herstellung von Säugetieren mit definierten genetischen Eigenschaften
|
US5948681A
(en)
*
|
1996-08-14 |
1999-09-07 |
Children's Hospital Of Philadelphia |
Non-viral vehicles for use in gene transfer
|
CN1181422A
(zh)
*
|
1996-10-31 |
1998-05-13 |
上海市肿瘤研究所 |
与生长因子受体结合的多肽所构建的基因转移载体
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
US5965441A
(en)
*
|
1996-11-13 |
1999-10-12 |
The General Hospital Coporation |
HSV/AAV hybrid amplicon vectors
|
US6797276B1
(en)
|
1996-11-14 |
2004-09-28 |
The United States Of America As Represented By The Secretary Of The Army |
Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
|
US20060002949A1
(en)
|
1996-11-14 |
2006-01-05 |
Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. |
Transcutaneous immunization without heterologous adjuvant
|
US5980898A
(en)
|
1996-11-14 |
1999-11-09 |
The United States Of America As Represented By The U.S. Army Medical Research & Material Command |
Adjuvant for transcutaneous immunization
|
WO1998027209A1
(en)
*
|
1996-12-18 |
1998-06-25 |
Emory University |
Polycationic oligomers
|
WO1998041240A1
(en)
*
|
1997-03-14 |
1998-09-24 |
The Children's Hospital Of Philadelphia |
Methods and compositions for use in gene therapy for treatment of hemophilia
|
AU7266898A
(en)
|
1997-04-30 |
1998-11-24 |
Enzon, Inc. |
Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
|
US20040009166A1
(en)
*
|
1997-04-30 |
2004-01-15 |
Filpula David R. |
Single chain antigen-binding polypeptides for polymer conjugation
|
US20050096288A1
(en)
*
|
1997-06-13 |
2005-05-05 |
Aragene, Inc. |
Lipoproteins as nucleic acid vectors
|
US6635623B1
(en)
|
1997-06-13 |
2003-10-21 |
Baylor College Of Medicine |
Lipoproteins as nucleic acid vectors
|
DE19726186A1
(de)
*
|
1997-06-20 |
1998-12-24 |
Boehringer Ingelheim Int |
Komplexe für den Transport von Nukleinsäure in höhere eukaryotische Zellen
|
US6172211B1
(en)
|
1997-07-11 |
2001-01-09 |
Boehringer Ingelheim International Gmbh |
Nucleic acid encoding tag7 polypeptide
|
WO1999002192A1
(en)
*
|
1997-07-11 |
1999-01-21 |
Brandeis University |
Method of inducing apoptosis by reducing the level of thiamin
|
EP1007673B1
(de)
|
1997-07-30 |
2008-12-17 |
Emory University |
Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
|
US7923250B2
(en)
|
1997-07-30 |
2011-04-12 |
Warsaw Orthopedic, Inc. |
Methods of expressing LIM mineralization protein in non-osseous cells
|
WO1999007723A1
(en)
*
|
1997-08-07 |
1999-02-18 |
University Of Maryland, Baltimore |
Nucleic acid uptake and release vehicle
|
US6706693B1
(en)
|
1997-08-13 |
2004-03-16 |
The Uab Research Foundation |
Vaccination by topical application of genetic vectors
|
US6716823B1
(en)
|
1997-08-13 |
2004-04-06 |
The Uab Research Foundation |
Noninvasive genetic immunization, expression products therefrom, and uses thereof
|
US6197332B1
(en)
|
1997-08-13 |
2001-03-06 |
Chiron Corporation |
Lipid-conjugated polyamide compounds and related compositions and methods thereof
|
US20030125278A1
(en)
*
|
1997-08-13 |
2003-07-03 |
Tang De-Chu C. |
Immunization of animals by topical applications of a salmonella-based vector
|
US6348450B1
(en)
|
1997-08-13 |
2002-02-19 |
The Uab Research Foundation |
Noninvasive genetic immunization, expression products therefrom and uses thereof
|
US20030045492A1
(en)
*
|
1997-08-13 |
2003-03-06 |
Tang De-Chu C. |
Vaccination by topical application of recombinant vectors
|
US5998386A
(en)
*
|
1997-09-19 |
1999-12-07 |
Feldman; Arthur M. |
Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
|
US6555367B1
(en)
*
|
1997-10-10 |
2003-04-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Complex of biotinylated viral vector and ligand for targeted gene delivery
|
BR9813930A
(pt)
|
1997-11-06 |
2006-12-19 |
Chiron Spa |
antìgeno neisserial
|
US6914131B1
(en)
|
1998-10-09 |
2005-07-05 |
Chiron S.R.L. |
Neisserial antigens
|
US6734338B1
(en)
|
1997-11-14 |
2004-05-11 |
Cedars-Sinai Medical Center |
Transfection, storage and transfer of male germ cells for generation of transgenic species and genetic therapies
|
US6316692B1
(en)
|
1997-11-14 |
2001-11-13 |
Cedars Sinai Medical Center |
Transfection, storage and transfer of male germ cells for generation of transgenic species and genetic therapies
|
US7294755B1
(en)
|
1997-11-14 |
2007-11-13 |
Cedars-Sinai Medical Center |
Genetic modification of male germ cells for generation of transgenic species and genetic therapies
|
EP0945138A1
(de)
*
|
1997-12-04 |
1999-09-29 |
Université Louis Pasteur de Strasbourg |
Partikeltransfektion
|
EP2138191A1
(de)
*
|
1998-01-05 |
2009-12-30 |
University Of Washington |
Erhöhter Transport unter Benutzung membranzerstörender Stoffe
|
EP1047784B2
(de)
|
1998-01-14 |
2015-03-18 |
Novartis Vaccines and Diagnostics S.r.l. |
Antigene aus neisseria meningitidis
|
WO1999055365A1
(en)
|
1998-04-30 |
1999-11-04 |
Cornell Research Foundation, Inc. |
Adenoviral vectors with tandem fiber proteins
|
NZ532665A
(en)
|
1998-05-01 |
2005-11-25 |
Inst Genomic Research |
Neisseria meningitidis antigens and compositions
|
US7244714B1
(en)
*
|
1998-06-12 |
2007-07-17 |
Aradigm Corporation |
Methods of delivering aerosolized polynucleotides to the respiratory tract
|
US6509323B1
(en)
|
1998-07-01 |
2003-01-21 |
California Institute Of Technology |
Linear cyclodextrin copolymers
|
US7091192B1
(en)
|
1998-07-01 |
2006-08-15 |
California Institute Of Technology |
Linear cyclodextrin copolymers
|
US6245427B1
(en)
|
1998-07-06 |
2001-06-12 |
DüZGüNES NEJAT |
Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles
|
US20040043489A1
(en)
*
|
1998-07-08 |
2004-03-04 |
Menzo Havenga |
Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
|
US20030017138A1
(en)
*
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
US7396919B1
(en)
*
|
1998-07-17 |
2008-07-08 |
Mirus Bio Corporation |
Charge reversal of polyion complexes
|
AU8818398A
(en)
|
1998-08-21 |
2000-03-14 |
Felix Frey |
Conjugates of dna interacting groups with steroid hormones for use as nucleic acid transfection agent
|
WO2000015823A1
(en)
|
1998-09-11 |
2000-03-23 |
Genvec, Inc. |
Alternatively targeted adenovirus
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
WO2000022130A2
(en)
|
1998-10-15 |
2000-04-20 |
Chiron Corporation |
Metastatic breast and colon cancer regulated genes
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
JP4854853B2
(ja)
|
1998-11-12 |
2012-01-18 |
ライフ テクノロジーズ コーポレーション |
トランスフェクション薬剤
|
EP1131457B1
(de)
|
1998-11-19 |
2010-10-06 |
Georgetown University |
Systemisches virus/ligand genabgabemittel und gentherapie
|
US20050063950A1
(en)
*
|
1998-11-19 |
2005-03-24 |
Georgetown University |
Systemic viral/ligand gene delivery system and gene therapy
|
US6929946B1
(en)
*
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
DE69939599D1
(de)
|
1998-12-16 |
2008-10-30 |
Novartis Vaccines & Diagnostic |
MENSCHLICHE CYCLIN-ABHÄNGIGE KINASE (hPNQALRE)
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
GB9908195D0
(en)
|
1999-04-09 |
1999-06-02 |
Microbiological Res Authority |
Treatment of intracellular infection
|
DE19918446A1
(de)
*
|
1999-04-23 |
2000-11-23 |
Univ Eberhard Karls |
Verwendung von Coxsackievirus B3 zur Verbesserung der Transfektion von Zellen
|
US6514762B1
(en)
|
1999-04-23 |
2003-02-04 |
New Mexico State University Technology Transfer Corporation |
Delivery of nucleotides by electrochemical release
|
NZ571167A
(en)
|
1999-04-30 |
2010-05-28 |
Novartis Vaccines & Diagnostic |
Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
|
US20040009936A1
(en)
*
|
1999-05-03 |
2004-01-15 |
Tang De-Chu C. |
Vaccine and drug delivery by topical application of vectors and vector extracts
|
US6913922B1
(en)
*
|
1999-05-18 |
2005-07-05 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US7468181B2
(en)
*
|
2002-04-25 |
2008-12-23 |
Crucell Holland B.V. |
Means and methods for the production of adenovirus vectors
|
US20050232900A1
(en)
*
|
1999-05-18 |
2005-10-20 |
Crucell Holland B.V. |
Serotype of adenovirus and uses thereof
|
US6492169B1
(en)
*
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
US6696272B1
(en)
|
1999-06-02 |
2004-02-24 |
Hsc Research & Development Limited Partnership |
Products and methods for gaucher disease therapy
|
US20080281041A1
(en)
*
|
1999-06-07 |
2008-11-13 |
Rozema David B |
Reversibly Masked Polymers
|
US8541548B2
(en)
*
|
1999-06-07 |
2013-09-24 |
Arrowhead Madison Inc. |
Compounds and methods for reversible modification of biologically active molecules
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
ES2183752T3
(es)
*
|
1999-09-17 |
2005-07-16 |
Tgt Laboratories, S.A. De C.V. |
Vectores adenovirales recombinantes y su utilizacion en el tratamiento de la cirrosis de higado.
|
EP2975127A1
(de)
|
1999-10-29 |
2016-01-20 |
GlaxoSmithKline Biologicals SA |
Neisseria antigenpeptide
|
CN1433478A
(zh)
*
|
1999-12-30 |
2003-07-30 |
诺瓦提斯公司 |
用于基因治疗的新的胶体合成载体
|
US7737108B1
(en)
*
|
2000-01-07 |
2010-06-15 |
University Of Washington |
Enhanced transport using membrane disruptive agents
|
EP2275129A3
(de)
|
2000-01-17 |
2013-11-06 |
Novartis Vaccines and Diagnostics S.r.l. |
Ergänzter Außenmembranvesikel-Impfstoff gegen Meningokokken
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
WO2001064920A2
(en)
|
2000-02-28 |
2001-09-07 |
Chiron Spa |
Hybrid expression of neisserial proteins
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
EP1157999A1
(de)
*
|
2000-05-24 |
2001-11-28 |
Introgene B.V. |
Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
|
EP1950297A2
(de)
|
2000-05-31 |
2008-07-30 |
Novartis Vaccines and Diagnostics, Inc. |
Zusammensetzungen und Verfahren zur Behandlung neoplastischer Erkrankungen mithilfe von Chemotherapie und Strahlungssensibilisatoren
|
WO2001092549A2
(en)
*
|
2000-05-31 |
2001-12-06 |
Genvec, Inc. |
Method and composition for targeting an adenoviral vector
|
US6881577B2
(en)
|
2000-06-28 |
2005-04-19 |
Max-Delbrück-Centrum für Molekulare Medizin |
Method for improving transfection efficiency
|
US20040058856A1
(en)
*
|
2000-07-26 |
2004-03-25 |
Soo-Young Choi |
Oligolysine transducing domain, oligolysine-cargo molecule complex and uses thereof
|
US7198924B2
(en)
|
2000-12-11 |
2007-04-03 |
Invitrogen Corporation |
Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
|
EP1322774A2
(de)
*
|
2000-09-20 |
2003-07-02 |
Crucell Holland B.V. |
Transduktion von dendritischen zellen durch verwendung der adenovirenvektoren
|
EP1191104A1
(de)
*
|
2000-09-26 |
2002-03-27 |
Introgene B.V. |
Genträger und deren Verwendung zur Herstellung von Arzneimitteln und/oder Impfstöffen
|
DE60138403D1
(de)
*
|
2000-09-26 |
2009-05-28 |
Crucell Holland Bv |
Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
|
DE10049010A1
(de)
*
|
2000-10-04 |
2002-04-18 |
Boehringer Ingelheim Int |
Transferrin-Polykation/DNS-Komplexe für die systemische Therapie von Tumorerkrankungen mit zytotoxischen Proteinen
|
SG165981A1
(en)
|
2000-10-27 |
2010-11-29 |
Chiron Srl |
Nucleic acids and proteins from streptococcus groups a & b
|
AU2002232387A1
(en)
*
|
2000-10-27 |
2002-05-06 |
Invitrogen Corporation |
Method for introducing antisense oligonucleotides into eucaryotic cells
|
US6892140B1
(en)
|
2000-11-27 |
2005-05-10 |
Enteron, Inc. |
Immunogenic cancer peptides and uses thereof
|
MXPA00011713A
(es)
*
|
2000-11-28 |
2002-05-31 |
Tgt Lab S A De C V |
Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe
|
US7635571B2
(en)
*
|
2000-12-07 |
2009-12-22 |
Siemens Healthcare Diagnostics Products Gmbh |
Amplified signal in binding assays
|
US6635466B2
(en)
*
|
2001-01-09 |
2003-10-21 |
University Of Iowa Research Foundation |
Adenovirus serotype 30 (Ad30)
|
AU2002240201A1
(en)
*
|
2001-02-02 |
2002-08-19 |
Yale University |
Peptides for facilitating composite receptor expression and translocation of macromolecules
|
WO2002064162A2
(en)
|
2001-02-13 |
2002-08-22 |
Government Of The United States, As Represented By The Secretary Of The Army |
Vaccine for transcutaneous immunization
|
WO2002079402A2
(en)
*
|
2001-03-23 |
2002-10-10 |
The Regents Of The University Of Michigan |
Method of inhibiting cancerous cell proliferation using ras mutants of gdp-bound conformation
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
US20020193295A1
(en)
*
|
2001-05-04 |
2002-12-19 |
Emanuel Calenoff |
Immunogenic peptides and uses thereof
|
US20030203865A1
(en)
*
|
2001-04-30 |
2003-10-30 |
Pierrot Harvie |
Lipid-comprising drug delivery complexes and methods for their production
|
WO2002089586A1
(en)
*
|
2001-05-10 |
2002-11-14 |
St. Jude Children's Research Hospital |
Lung epithelial cell line for propagating viruses
|
US20060159657A1
(en)
*
|
2001-06-14 |
2006-07-20 |
Macromed, Incorporated |
Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
|
US20030003074A1
(en)
*
|
2001-06-14 |
2003-01-02 |
Macromed, Inc. |
Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
EP1992643A3
(de)
|
2001-06-20 |
2008-12-10 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
CA2790034A1
(en)
|
2001-06-21 |
2003-01-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
GB0120022D0
(en)
*
|
2001-08-16 |
2001-10-10 |
Photobiotics Ltd |
Conjugate
|
WO2003024392A2
(en)
|
2001-09-18 |
2003-03-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20060199778A1
(en)
*
|
2001-09-19 |
2006-09-07 |
Rutledge Ellis-Behnke |
Methods and products related to non-viral transfection
|
NZ566396A
(en)
|
2001-10-09 |
2009-07-31 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
US7745418B2
(en)
*
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
WO2003088808A2
(en)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
IL161733A0
(en)
|
2001-11-02 |
2005-11-20 |
Insert Therapeutics Inc |
Methods and compositions for therapeutic use of rna interference
|
AU2002348163A1
(en)
*
|
2001-11-02 |
2003-05-19 |
Intradigm Corporation |
Therapeutic methods for nucleic acid delivery vehicles
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
EP2335723A1
(de)
|
2001-12-12 |
2011-06-22 |
Novartis Vaccines and Diagnostics S.r.l. |
Immunisierung gegen Chlamydia trachomatis
|
EP1575571A4
(de)
|
2002-01-02 |
2008-06-25 |
Genentech Inc |
Zusammensetzungen und verfahren zur diagnose und behandlung eines tumors
|
US8008355B2
(en)
*
|
2002-03-11 |
2011-08-30 |
Roche Madison Inc. |
Endosomolytic poly(vinyl ether) polymers
|
US8138383B2
(en)
*
|
2002-03-11 |
2012-03-20 |
Arrowhead Madison Inc. |
Membrane active heteropolymers
|
WO2003078576A2
(en)
*
|
2002-03-12 |
2003-09-25 |
Nitto Denko Corporation |
Vector for transfection of eukaryotic cells
|
AU2003267949A1
(en)
*
|
2002-03-15 |
2003-12-31 |
U.S. Government As Represented By The Department Of Veterans Affairs |
Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
US20040142450A1
(en)
*
|
2002-05-10 |
2004-07-22 |
Seo Sang Heui |
Lung epithelial cell line for propagating viruses
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
US20050233993A1
(en)
*
|
2002-06-05 |
2005-10-20 |
Kadonaga James T |
Methods for promoting homologous recombination
|
EP1515752B1
(de)
|
2002-06-19 |
2008-11-26 |
University Health Network |
Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck
|
US20060003316A1
(en)
*
|
2002-07-15 |
2006-01-05 |
John Simard |
Immunogenic compositions derived from poxviruses and methods of using same
|
KR20120104412A
(ko)
|
2002-09-06 |
2012-09-20 |
인설트 테라페틱스, 인코퍼레이티드 |
공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
|
US20050260601A1
(en)
*
|
2002-09-09 |
2005-11-24 |
Whitt Michael A |
Recombinant mutants of rhabdovirus and methods of use thereof
|
EP1537208A1
(de)
|
2002-09-13 |
2005-06-08 |
Replicor, Inc. |
Nicht-sequenzkomplementäre antivirale oligonukleotide
|
WO2004031350A2
(en)
|
2002-09-26 |
2004-04-15 |
Amgen, Inc. |
Modulation of forkhead box o1a expression
|
CN1711475A
(zh)
*
|
2002-10-10 |
2005-12-21 |
退伍军人事务部 |
利用已标记的、针对肿瘤特异性表位的活化淋巴细胞进行肿瘤的检测、定位和分级
|
CA2504720C
(en)
|
2002-11-05 |
2013-12-24 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
WO2004044139A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Parmaceuticals, Inc. |
Modified oligonucleotides for use in rna interference
|
US20080026077A1
(en)
*
|
2002-11-12 |
2008-01-31 |
John Hilfinger |
Methods and compositions of gene delivery agents for systemic and local therapy
|
US20050026859A1
(en)
*
|
2002-11-12 |
2005-02-03 |
John Hilfinger |
Methods and compositions of gene delivery agents for systemic and local therapy
|
DK1569695T3
(da)
|
2002-11-13 |
2013-08-05 |
Genzyme Corp |
Antisense-modulering af apolipoprotein-b-ekspression
|
CA2505801A1
(en)
|
2002-11-13 |
2004-05-27 |
Rosanne Crooke |
Antisense modulation of apolipoprotein b expression
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
NZ541637A
(en)
|
2003-02-11 |
2008-07-31 |
Antisense Therapeutics Pty Ltd |
Modulation of insulin like growth factor I receptor
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US7217566B2
(en)
*
|
2003-03-24 |
2007-05-15 |
Invitrogen Corporation |
Attached cell lines
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
AU2004231740A1
(en)
*
|
2003-04-17 |
2004-11-04 |
The Trustees Of Columbia University In The City Ofnew York |
Desmoglein 4 is a novel gene involved in hair growth
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
US20040220084A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods for nucleic acid delivery
|
US20040220085A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Compositions for nucleic acid delivery
|
CN1984921B
(zh)
|
2003-06-03 |
2010-06-16 |
Isis药物公司 |
存活蛋白表达的调节
|
CA2528094A1
(en)
*
|
2003-06-09 |
2005-01-13 |
Corixa Corporation |
Expression vectors for stimulating an immune response to cancer antigens
|
WO2005007819A2
(en)
*
|
2003-07-09 |
2005-01-27 |
Wisconsin Alumni Research Foundation |
Charge-dynamic polymers and delivery of anionic compounds
|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
EP1668130A2
(de)
|
2003-09-18 |
2006-06-14 |
Isis Pharmaceuticals, Inc. |
Modulation der eif4e-expression
|
ES2437491T3
(es)
|
2003-10-10 |
2014-01-10 |
Alchemia Oncology Pty Limited |
Modulación de la síntesis y degradación de hialuronano en el tratamiento de enfermedad
|
EP2267154A1
(de)
|
2003-10-23 |
2010-12-29 |
Illumigen Biosciences, Inc. |
Oligoadenylate Synthetase
|
US8133733B2
(en)
|
2003-10-24 |
2012-03-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to target tissues
|
EP2418281B1
(de)
|
2003-10-24 |
2016-06-01 |
Gencia Corporation |
Verfahren und Zusammensetzungen zur Abgabe von Polynukleotiden
|
US20090208478A1
(en)
*
|
2003-10-24 |
2009-08-20 |
Gencia Corporation |
Transducible polypeptides for modifying metabolism
|
US8507277B2
(en)
|
2003-10-24 |
2013-08-13 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides
|
US20090123468A1
(en)
|
2003-10-24 |
2009-05-14 |
Gencia Corporation |
Transducible polypeptides for modifying metabolism
|
US8062891B2
(en)
|
2003-10-24 |
2011-11-22 |
Gencia Corporation |
Nonviral vectors for delivering polynucleotides to plants
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
EP1689432B1
(de)
|
2003-11-17 |
2009-12-30 |
Genentech, Inc. |
Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs
|
EP2287341B1
(de)
|
2003-12-01 |
2013-02-13 |
Life Technologies Corporation |
Rekombinationsstellen enthaltende Nukleinsäuremoleküle und Verfahren zur Verwendung davon
|
SG113562A1
(en)
*
|
2004-01-12 |
2005-08-29 |
Agency Science Tech & Res |
Polyalkyleneimine-graft-biodegradable polymers for delivery of bioactive agents
|
EP2363480A3
(de)
|
2004-01-20 |
2015-10-07 |
Isis Pharmaceuticals, Inc. |
Modulierung der Glukokortikoid-Rezeptor-Expression
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
WO2005069987A2
(en)
*
|
2004-01-23 |
2005-08-04 |
City Of Hope |
Amplifying interfering rna (rnai) expression and effects
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
US20050203047A1
(en)
*
|
2004-03-10 |
2005-09-15 |
Ulrich Thomann |
Delivery vectors for short interfering RNA, micro-RNA and antisense RNA
|
WO2005089268A2
(en)
|
2004-03-15 |
2005-09-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of rna by rnase h
|
JP5184077B2
(ja)
*
|
2004-03-26 |
2013-04-17 |
キュリス,インコーポレイテッド |
ヘッジホッグシグナリングのrna干渉モジュレーター及びその利用
|
CN104292321A
(zh)
|
2004-03-29 |
2015-01-21 |
株式会社嘉尔药物 |
新的半乳凝素9 突变体蛋白质及其用途
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
US8697139B2
(en)
|
2004-09-21 |
2014-04-15 |
Frank M. Phillips |
Method of intervertebral disc treatment using articular chondrocyte cells
|
JP5101288B2
(ja)
|
2004-10-05 |
2012-12-19 |
カリフォルニア インスティテュート オブ テクノロジー |
アプタマー調節される核酸及びその利用
|
AU2005294265A1
(en)
|
2004-10-06 |
2006-04-20 |
University Of Rochester |
Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
|
US7833513B2
(en)
|
2004-12-03 |
2010-11-16 |
Rhode Island Hospital |
Treatment of Alzheimer's Disease
|
EP1856526A4
(de)
|
2005-01-20 |
2008-11-12 |
Univ Rochester |
Mit thioredoxin interagierendes protein (txnip) als regulator der gefässfunktion
|
CA2596506C
(en)
|
2005-02-09 |
2021-04-06 |
Avi Biopharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
AU2006216671A1
(en)
*
|
2005-02-23 |
2006-08-31 |
The Uab Research Foundation |
Alkyl-glycoside enhanced vaccination
|
CN101175769A
(zh)
|
2005-03-10 |
2008-05-07 |
健泰科生物技术公司 |
用于调控血管完整性的方法和组合物
|
ES2381201T3
(es)
|
2005-03-31 |
2012-05-24 |
Calando Pharmaceuticals, Inc. |
Inhibidores de la subunidad 2 de la ribonucleótido-reductasa y utilizaciones de los mismos
|
US8734851B2
(en)
*
|
2005-04-29 |
2014-05-27 |
Wisconsin Alumni Research Foundation |
Localized delivery of nucleic acid by polyelectrolyte assemblies
|
UA95446C2
(ru)
|
2005-05-04 |
2011-08-10 |
Іллюміджен Байосайєнсіз, Інк. |
Мутаци в генах oas1
|
DE102005023993A1
(de)
*
|
2005-05-20 |
2006-11-23 |
TransMIT Gesellschaft für Technologietransfer mbH |
Nicht virales Vektorsystem zum Transport von Nukleinsäure in die Lunge
|
WO2007062380A2
(en)
|
2005-11-21 |
2007-05-31 |
Isis Pharmaceuticals, Inc. |
Modulation of eif4e-bp2 expression
|
US20090068158A1
(en)
*
|
2005-12-09 |
2009-03-12 |
Medin Jeffrey A |
Thymidylate kinase mutants and uses thereof
|
CA2566267A1
(en)
*
|
2005-12-09 |
2007-06-09 |
University Health Network |
Thymidylate kinase mutants and uses thereof
|
WO2007067733A2
(en)
*
|
2005-12-09 |
2007-06-14 |
Massachusetts Institute Of Technology |
Compositions and methods to monitor rna delivery to cells
|
EP3210633B1
(de)
|
2006-01-26 |
2019-06-19 |
Ionis Pharmaceuticals, Inc. |
Zusammensetzungen und deren verwendungen in bezug auf huntingtin
|
CA2638915A1
(en)
*
|
2006-02-10 |
2007-08-23 |
The Regents Of The University Of California |
Transducible delivery of sirna by dsrna binding domain fusions to ptd/cpps
|
EP2514824A3
(de)
|
2006-03-03 |
2013-01-23 |
Amorfix Life Sciences Ltd. |
Verfahren und Zusammensetzungen zum Behandeln und Erkennen von missgefaltetem SOD 1-herbeigeführte Erkrankungen
|
US7718193B2
(en)
*
|
2006-03-16 |
2010-05-18 |
University Of Washington |
Temperature- and pH-responsive polymer compositions
|
EP2614839A3
(de)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Verfahren zur Verwendung von BOC/CDO zur Modulation der Hedgehog-Signalisierung
|
WO2007125173A2
(en)
|
2006-05-03 |
2007-11-08 |
Baltic Technology Development, Ltd. |
Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
|
ATE522541T1
(de)
|
2006-06-09 |
2011-09-15 |
Novartis Ag |
Bakterielle adhäsine konformere
|
CA2659103C
(en)
*
|
2006-07-12 |
2019-05-21 |
The Regents Of The University Of California |
Transducible delivery of nucleic acids by reversible phosphotriester charge neutralization protecting groups
|
WO2008011473A2
(en)
|
2006-07-19 |
2008-01-24 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to hbxip
|
CN102614528B
(zh)
*
|
2006-08-18 |
2014-02-26 |
箭头研究公司 |
用于体内递送多核苷酸的多缀合物
|
US8017109B2
(en)
*
|
2006-08-18 |
2011-09-13 |
Roche Madison Inc. |
Endosomolytic poly(acrylate) polymers
|
US9308198B2
(en)
|
2006-09-08 |
2016-04-12 |
Rhode Island Hospital |
Treatment, prevention, and reversal of alcohol-induced brain disease
|
ES2399147T3
(es)
|
2006-09-08 |
2013-03-26 |
Rhode Island Hospital |
Tratamiento, prevención y reversión de una enfermedad hepática alcohólica
|
US8158595B2
(en)
|
2006-11-09 |
2012-04-17 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
WO2008073856A2
(en)
*
|
2006-12-08 |
2008-06-19 |
Massachusetts Institute Of Technology |
Delivery of nanoparticles and/or agents to cells
|
EP2118118B1
(de)
*
|
2007-01-19 |
2017-09-27 |
Exiqon A/S |
Vermittelte zelluläre verabreichung von lna-oligonukleotiden
|
US8834918B2
(en)
*
|
2007-01-22 |
2014-09-16 |
Wisconsin Alumni Research Foundation |
Modified multilayered film
|
JP2010516625A
(ja)
|
2007-01-24 |
2010-05-20 |
インサート セラピューティクス, インコーポレイテッド |
制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
|
WO2008094945A2
(en)
|
2007-01-29 |
2008-08-07 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
WO2009045469A2
(en)
|
2007-10-02 |
2009-04-09 |
Amgen Inc. |
Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
|
US7875431B2
(en)
|
2007-02-22 |
2011-01-25 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
US7981688B2
(en)
|
2007-03-08 |
2011-07-19 |
University Of Washington |
Stimuli-responsive magnetic nanoparticles and related methods
|
WO2008116116A2
(en)
|
2007-03-20 |
2008-09-25 |
Harold Brem |
Gm-csf cosmeceutical compositions and methods of use thereof
|
CA2584494A1
(en)
*
|
2007-03-27 |
2008-09-27 |
Jeffrey A. Medin |
Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
|
ES2654303T3
(es)
|
2007-05-04 |
2018-02-13 |
University Health Network |
Inmunoterapia de IL-12 contra el cáncer
|
WO2009011855A2
(en)
*
|
2007-07-16 |
2009-01-22 |
California Institute Of Technology |
Selection of nucleic acid-based sensor domains within nucleic acid switch platform
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
US8367815B2
(en)
*
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
US8865667B2
(en)
*
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
WO2009049100A2
(en)
*
|
2007-10-09 |
2009-04-16 |
Wisconsin Alumni Research Foundation |
Ultrathin multilayered films for controlled release of anionic reagents
|
US9029524B2
(en)
*
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
EP2077119A1
(de)
*
|
2007-12-21 |
2009-07-08 |
Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. |
Behandlung von Fibrosen und Lebererkrankungen
|
US8344116B2
(en)
*
|
2008-03-17 |
2013-01-01 |
Case Western Reserve University |
Polymers and complexes for delivery of nucleic acids to intracellular targets
|
US8568709B2
(en)
*
|
2008-03-20 |
2013-10-29 |
University Health Network |
Thymidylate kinase fusions and uses thereof
|
US8114983B2
(en)
|
2008-04-04 |
2012-02-14 |
Calando Pharmaceuticals, Inc. |
Compositions and use of EPAS1 inhibitors
|
GB2459436A
(en)
*
|
2008-04-08 |
2009-10-28 |
Henderson Morley Plc |
Vaccine adjuvant
|
US8324333B2
(en)
*
|
2008-06-05 |
2012-12-04 |
Wisconsin Alumni Research Foundation |
Anionic charge-dynamic polymers for release of cationic agents
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
EP3081648A1
(de)
|
2008-08-25 |
2016-10-19 |
Excaliard Pharmaceuticals, Inc. |
Gegen den bindegewebe-wachstumsfaktor gerichtete antisense-oligonukleotide und verwendungen davon
|
US10138485B2
(en)
|
2008-09-22 |
2018-11-27 |
Rxi Pharmaceuticals Corporation |
Neutral nanotransporters
|
US20110294870A1
(en)
|
2008-12-04 |
2011-12-01 |
Opko Curna, Llc |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
ES2629630T3
(es)
|
2008-12-04 |
2017-08-11 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
|
CN102307997B
(zh)
|
2008-12-04 |
2018-03-30 |
库尔纳公司 |
通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1(sirt1)相关的疾病
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
CN102439149B
(zh)
|
2009-02-12 |
2018-01-02 |
库尔纳公司 |
通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
|
ES2762610T3
(es)
|
2009-02-12 |
2020-05-25 |
Curna Inc |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
ES2845644T3
(es)
|
2009-03-04 |
2021-07-27 |
Curna Inc |
Tratamiento de enfermedades relacionadas con sirtuina1 (SIRT1) mediante inhibición del transcrito del antisentido natural a sirtuina 1
|
MX2011009751A
(es)
|
2009-03-16 |
2011-09-29 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2.
|
WO2010107740A2
(en)
|
2009-03-17 |
2010-09-23 |
Curna, Inc. |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
WO2010107991A2
(en)
|
2009-03-18 |
2010-09-23 |
Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
EP3524275A1
(de)
|
2009-04-22 |
2019-08-14 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung ermöglicht die wiederholte verabreichung von langen rna-molekülen
|
EP2424987B1
(de)
|
2009-05-01 |
2017-11-15 |
CuRNA, Inc. |
Behandlung von hämoglobin (hbf / hbg) verwandten krankheiten durch die inhibition des natürlichen antisense transcripts zu hbf / hbg
|
CN102459596B
(zh)
|
2009-05-06 |
2016-09-07 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
JP6250930B2
(ja)
|
2009-05-06 |
2017-12-20 |
クルナ・インコーポレーテッド |
トリステトラプロリン(ttp)に対する天然アンチセンス転写物の抑制によるttp関連疾患の治療
|
CN102575251B
(zh)
|
2009-05-18 |
2018-12-04 |
库尔纳公司 |
通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病
|
KR101703695B1
(ko)
|
2009-05-22 |
2017-02-08 |
큐알엔에이, 인크. |
전사 인자 e3(tfe3)에 대한 천연 안티센스 전사체의 억제에 의해 tfe3 및 인슐린 수용체 기질 2(irs2)의 치료
|
CN103221541B
(zh)
|
2009-05-28 |
2017-03-01 |
库尔纳公司 |
通过抑制抗病毒基因的天然反义转录物来治疗抗病毒基因相关疾病
|
CA3120504A1
(en)
|
2009-06-10 |
2010-12-16 |
New York University |
Immunological targeting of pathological tau proteins
|
US8426214B2
(en)
*
|
2009-06-12 |
2013-04-23 |
University Of Washington |
System and method for magnetically concentrating and detecting biomarkers
|
KR101702689B1
(ko)
|
2009-06-16 |
2017-02-06 |
큐알엔에이, 인크. |
Pon1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(pon1) 관련된 질환의 치료
|
WO2010148050A2
(en)
|
2009-06-16 |
2010-12-23 |
Curna, Inc. |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
CA2765889A1
(en)
|
2009-06-24 |
2010-12-29 |
Opko Curna, Llc |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
CA2765815A1
(en)
|
2009-06-26 |
2010-12-29 |
Opko Curna, Llc |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
US9234199B2
(en)
|
2009-08-05 |
2016-01-12 |
Curna, Inc. |
Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS)
|
CN102482671B
(zh)
|
2009-08-25 |
2017-12-01 |
库尔纳公司 |
通过抑制‘含有iq模体的gtp酶激活蛋白’(iqgap)的天然反义转录物而治疗iqgap相关疾病
|
US9321823B2
(en)
|
2009-09-02 |
2016-04-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CA2780741C
(en)
|
2009-10-12 |
2023-04-04 |
Smith Holdings, Llc |
Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
|
BR112012009409A2
(pt)
|
2009-10-22 |
2017-02-21 |
Genentech Inc |
método de identificação de uma substância inibidora, molécula antagonista, ácido nucleico isolado, vetor, célula hospedeira, método para fabricar a molécula, composição, artigo de fabricação, método de inibição de uma atividade biológica, método de tratamento de uma condição patológica, método para detectar msp em uma amostra e método para detectar hepsina em uma amostra
|
WO2011052804A1
(en)
*
|
2009-10-30 |
2011-05-05 |
Tokyo University Of Science Educational Foundation Administrative Organization |
Method of delivering agent into target cell
|
US20120244169A1
(en)
|
2009-11-06 |
2012-09-27 |
Fibrogen, Inc. |
Treatment for Radiation-Induced Disorders
|
US20110117668A1
(en)
*
|
2009-11-09 |
2011-05-19 |
University Of Washington Through Its Center For Commercialization |
Self-powered smart diagnostic devices
|
US9080933B2
(en)
|
2009-11-09 |
2015-07-14 |
University Of Washington Through Its Center For Commercialization |
Stimuli-responsive polymer diagnostic assay comprising magnetic nanoparticles and capture conjugates
|
CN102781237A
(zh)
*
|
2009-11-23 |
2012-11-14 |
天蓝制药公司 |
用于传递治疗剂的基于环糊精的聚合物
|
AR079217A1
(es)
|
2009-11-30 |
2012-01-04 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores
|
MX2012006580A
(es)
|
2009-12-11 |
2012-09-28 |
Genecode As |
Metodo para facilitar la sobrevivencia de celulas neurales usando mimeticos de ligandos (gfl) de la familia gdnf o activadores de la ruta de señalizacion de ret.
|
ES2661813T3
(es)
|
2009-12-16 |
2018-04-04 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la peptidasa del factor de transcripción de membrana, sitio 1 (mbtps1) mediante inhibición del transcrito antisentido natural al gen mbtps1
|
US9068183B2
(en)
|
2009-12-23 |
2015-06-30 |
Curna, Inc. |
Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
|
CA2782373C
(en)
|
2009-12-23 |
2019-03-26 |
Opko Curna, Llc |
Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
|
WO2011090740A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
ES2585829T3
(es)
|
2009-12-29 |
2016-10-10 |
Curna, Inc. |
Tratamiento de las enfermedades relacionadas con la proteína tumoral 63 (p63) por inhibición de transcripción antisentido natural a p63
|
KR101878501B1
(ko)
|
2010-01-04 |
2018-08-07 |
큐알엔에이, 인크. |
인터페론 조절 인자 8 (irf8)에 대한 자연 안티센스 전사체의 저해에 의한 인터페론 조절 인자 8 (irf8) 관련된 질환의 치료
|
EP2521785B1
(de)
|
2010-01-06 |
2022-03-09 |
CuRNA, Inc. |
Inhibition des natürlichen antisense-transkripts des pankreasentwicklungsgens zur verwendung in der behandlung von pankreatischen entwicklungsgenbezogenen krankheiten
|
DK2524039T3
(en)
|
2010-01-11 |
2018-03-12 |
Curna Inc |
TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
|
US8883739B2
(en)
|
2010-01-19 |
2014-11-11 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for male reproductive disorders
|
CN102782135A
(zh)
|
2010-01-25 |
2012-11-14 |
库尔纳公司 |
通过抑制rna酶h1的天然反义转录物而治疗rna酶h1相关疾病
|
CN102844435B
(zh)
|
2010-02-22 |
2017-05-10 |
库尔纳公司 |
通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
|
MX2012009215A
(es)
|
2010-02-23 |
2012-11-23 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
NZ601737A
(en)
*
|
2010-02-24 |
2013-06-28 |
Arrowhead Res Corp |
Compositions for targeted delivery of sirna
|
RU2610661C2
(ru)
|
2010-04-09 |
2017-02-14 |
Курна, Инк. |
Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21
|
US8362207B2
(en)
|
2010-04-16 |
2013-01-29 |
Wake Forest University Health Sciences |
Multi-level specific targeting of cancer cells with IL-13
|
WO2011139917A1
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression
|
MA34291B1
(fr)
|
2010-05-03 |
2013-06-01 |
Genentech Inc |
Compositions et méthodes de diagnostic et de traitement d'une tumeur
|
CN107988228B
(zh)
|
2010-05-03 |
2022-01-25 |
库尔纳公司 |
通过抑制沉默调节蛋白(sirt)的天然反义转录物而治疗沉默调节蛋白(sirt)相关疾病
|
JP5866106B2
(ja)
|
2010-05-12 |
2016-02-17 |
コロンビア ユニヴァーシティ |
インスリンを産生し分泌する腸内分泌細胞の製造方法
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
US8895528B2
(en)
|
2010-05-26 |
2014-11-25 |
Curna, Inc. |
Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
|
WO2012008361A1
(ja)
|
2010-07-10 |
2012-01-19 |
財団法人北九州産業学術推進機構 |
細胞への核酸導入方法および核酸複合体
|
CN103068982B
(zh)
|
2010-07-14 |
2017-06-09 |
库尔纳公司 |
通过抑制盘状大同系物(dlg)的天然反义转录物而治疗dlg相关疾病
|
WO2012047968A2
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP2625274B1
(de)
|
2010-10-06 |
2017-07-19 |
CuRNA, Inc. |
Behandlung sialidase-4-(neu4)-vermittelter erkrankungen durch hemmung des natürlichen antisense-transkripts gegen neu4
|
CA2815212A1
(en)
|
2010-10-22 |
2012-04-26 |
Curna, Inc. |
Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
|
JP6073795B2
(ja)
|
2010-10-27 |
2017-02-01 |
カッパーアールエヌエー,インコーポレイテッド |
インターフェロン関連発生制御因子1(ifrd1)への天然アンチセンス転写物の阻害によるifrd1関連疾患の治療
|
WO2012061811A2
(en)
|
2010-11-05 |
2012-05-10 |
Fibrogen, Inc. |
Treatment method for lung remodeling diseases
|
DK2638149T3
(da)
|
2010-11-12 |
2019-08-12 |
Univ Georgetown |
Immortalisering af epitelceller og fremgangsmåder til anvendelse
|
CN103459599B
(zh)
|
2010-11-23 |
2017-06-16 |
库尔纳公司 |
通过抑制nanog的天然反义转录物而治疗nanog相关疾病
|
EP2658567A4
(de)
|
2010-12-28 |
2014-09-24 |
Univ Rochester |
Verfahren zur modifikation einer insulinsignalübertragung mittels biliverdinreduktase (bvr) und bvr-abgeleiteten peptiden
|
WO2012106508A1
(en)
|
2011-02-02 |
2012-08-09 |
Pfizer Inc. |
Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
CN103561725B
(zh)
|
2011-03-14 |
2018-08-31 |
国立大学法人北海道大学 |
用于肺递送的载体、导入剂及用途
|
AU2012242642A1
(en)
|
2011-04-13 |
2013-05-02 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
JP6188686B2
(ja)
|
2011-06-09 |
2017-08-30 |
カッパーアールエヌエー,インコーポレイテッド |
フラタキシン(fxn)への天然アンチセンス転写物の阻害によるfxn関連疾患の治療
|
CN103597074A
(zh)
|
2011-06-16 |
2014-02-19 |
Isis制药公司 |
成纤维细胞生长因子受体4表达的反义调节
|
US10350277B2
(en)
|
2011-09-07 |
2019-07-16 |
Icahn School Of Medicine At Mount Sinai |
Ceramidase and cell differentiation
|
CN103814132B
(zh)
|
2011-09-20 |
2018-06-05 |
苏州瑞博生物技术有限公司 |
Gcgr表达的反义调节
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
CN103906838A
(zh)
|
2011-10-25 |
2014-07-02 |
Isis制药公司 |
Gccr表达的反义调节
|
US20150031750A1
(en)
|
2012-03-15 |
2015-01-29 |
The Scripps Research Institute |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
EP2885313A4
(de)
|
2012-08-20 |
2016-03-09 |
Univ California |
Polynukleotide mit bioreversiblen gruppen
|
WO2014041179A1
(en)
|
2012-09-17 |
2014-03-20 |
Chemedest Ltd. |
Treatment of peripheral neuropathy using gfr(alpha)3 type receptor agonists
|
WO2014055493A1
(en)
|
2012-10-02 |
2014-04-10 |
Cerulean Pharma Inc. |
Methods and systems for polymer precipitation and generation of particles
|
US9694050B2
(en)
|
2012-10-21 |
2017-07-04 |
University Of Rochester |
THY1 (CD90) as a novel therapy to control adipose tissue accumulation
|
EP2920319B1
(de)
|
2012-11-16 |
2020-02-19 |
Poseida Therapeutics, Inc. |
Ortsspezifische enzyme und verfahren zur verwendung
|
WO2014152497A2
(en)
|
2013-03-15 |
2014-09-25 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for cognitive disorders
|
US9822418B2
(en)
|
2013-04-22 |
2017-11-21 |
Icahn School Of Medicine At Mount Sinai |
Mutations in PDGFRB and NOTCH3 as causes of autosomal dominant infantile myofibromatosis
|
CA2918787A1
(en)
|
2013-06-13 |
2014-12-18 |
George Tachas |
Combination therapy
|
US20150197534A1
(en)
|
2013-09-05 |
2015-07-16 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
WO2015042466A2
(en)
|
2013-09-19 |
2015-03-26 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for inhibiting jc virus (jcv)
|
WO2015070210A1
(en)
|
2013-11-11 |
2015-05-14 |
Wake Forest University Health Sciences |
Epha3 and multi-valent targeting of tumors
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
WO2015120075A2
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
JP6753843B2
(ja)
|
2014-05-14 |
2020-09-16 |
タルグルムーネ セラピウティクス エージー |
改善されたポリエチレンイミンポリエチレングリコールベクター
|
WO2015176737A1
(en)
*
|
2014-05-19 |
2015-11-26 |
Biontech Ag |
Particles comprising protamine and rna in combination with endosome destabilizing agents
|
CA2985344A1
(en)
|
2014-06-26 |
2015-12-30 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
|
WO2016011203A1
(en)
|
2014-07-15 |
2016-01-21 |
Life Technologies Corporation |
Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
WO2016081728A1
(en)
|
2014-11-19 |
2016-05-26 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for frailty associated with aging
|
US20170369872A1
(en)
|
2014-12-18 |
2017-12-28 |
Alnylam Pharmaceuticals, Inc. |
Reversir tm compounds
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
EP3851531A1
(de)
|
2015-06-01 |
2021-07-21 |
Sarepta Therapeutics, Inc. |
Antisense-induzierte exonexklusion in typ-vii-kollagen
|
CN108026519A
(zh)
|
2015-06-17 |
2018-05-11 |
波赛达治疗公司 |
将蛋白质定向至基因组中的特定基因座的组合物和方法
|
US10954300B2
(en)
|
2015-09-28 |
2021-03-23 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
JP2018530560A
(ja)
|
2015-10-09 |
2018-10-18 |
サレプタ セラピューティクス, インコーポレイテッド |
デュシェンヌ型筋ジストロフィーおよび関連障害の処置のための組成物および方法
|
EP3371211A4
(de)
|
2015-11-04 |
2019-08-21 |
Icahn School of Medicine at Mount Sinai |
Verfahren zur behandlung von tumoren und krebs sowie identifizierung von kandidatenpatienten für solch eine behandlung
|
EP3370734B1
(de)
|
2015-11-05 |
2023-01-04 |
Children's Hospital Los Angeles |
Antisense-oligo zur verwendung bei der behandlung von akuter myeloischer leukämie
|
CA3019952A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
KR102522059B1
(ko)
|
2016-04-18 |
2023-04-14 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
안티센스 올리고머, 및 산성 알파-글루코시다제 유전자와 연관된 질환을 치료하기 위한 이의 사용 방법
|
US11246868B2
(en)
|
2016-04-26 |
2022-02-15 |
Icahn School Of Medicine At Mount Sinai |
Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment
|
US10994025B2
(en)
|
2017-05-12 |
2021-05-04 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded RNA complexes and uses related thereto
|
WO2019006455A1
(en)
|
2017-06-30 |
2019-01-03 |
Solstice Biologics, Ltd. |
AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
|
WO2019079637A2
(en)
|
2017-10-18 |
2019-04-25 |
Sarepta Therapeutics, Inc. |
ANTISENSE OLIGOMERIC COMPOUNDS
|
WO2019126578A1
(en)
|
2017-12-20 |
2019-06-27 |
Poseida Therapeutics, Inc. |
Compositions and methods for directing proteins to specific loci in the genome
|
US20210155959A1
(en)
|
2018-04-06 |
2021-05-27 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
AU2022261124A1
(en)
|
2021-04-22 |
2023-10-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating cancer
|